Mark Davis

Thoughts are the voices in my head, not financial advice. I am not a financial advisor posts are my own opinions. Do your own DD watch your own money!

[Mark Davis @Icon_of_OTC]

HUGE Day for $MAJI and the shareholders! Court is a game of chess, each move must be calculated. According to the Clerk of the Courts, Depositions are set for January 5, 2025 for Steinberg and Carlson.

[NextTel Medical Corp @NexTelMedical]

Exousia Pro $MAJI Shareholder Update: We are pleased to report a significant legal victory that supports our commitment to maximizing shareholder value. Following the hearing on December 16, 2025, the Court issued a favorable ruling, DENYING the Motion to Dismiss filed by Don Steinberg and Kimberly Carlson. This decision validates the strength of our claims and allows us to aggressively move forward to pursue justice on behalf of our shareholders. We remain dedicated to a positive and decisive outcome.

[@ExousiaBio @ExousiaBio]

https://t.co/byeneKUzOn

[NextTel Medical Corp @NexTelMedical]

Exousia Pro - $MAJI - unveils the full spectrum power of Maxasome™! This isn't just a supplement—it's cellular armor delivered by 100% Pure Exosomal Technology. Maxasome™, derived from Yellow Oyster Mushrooms, provides a potent, natural blend of Ergothioneine (EGT), Beta-glucans, and Vitamin D2. The sublingual (under the tongue) dropper ensures rapid delivery directly to your mitochondria and cell nucleus, providing unmatched protection for Longevity and Cognitive Vitality. Help Maximize your healthspan!

[NextTel Medical Corp @NexTelMedical]

$MAJI - new supplement Maxasome™ health benefits:

[@ExousiaBio @ExousiaBio]

$LMMY Interview with Dr. Marvin Hausman

https://t.co/Jo3TOkY0TL

[NextTel Medical Corp @NexTelMedical]

$MAJI
We are launching a premarket IRB approved clinical study, to validate our patented state-of-the-art NANOG DNA cancer screening test.

[@ExousiaBio @ExousiaBio]

$LMMY releases news on it acquisition.
https://t.co/opjAym4NsM

[@ExousiaBio @ExousiaBio]

Welcome Shareholders to the Official “X” Account for Exousia Bio Inc. ( $LMMY ) - In just a few days, we will begin to release our first major update, formally kicking off what we believe will be a transformative and thrilling journey for the company.

[Valentina OTC @ValentinaOTC]

$MAJI - Seriously, check the DD, and you will see once that group from court case runs out of shares, this thing is gonna moon.
@Icon_of_OTC @MicroCapTweets @SuperRobotGX @cdntradegrljenn @thommic

[ONAR @BuiltWithOnar]

The momentum is real.

Less than a month after acquiring JUICE, we've already secured over $250,000 in new recurring annual revenue and expanded a top client's contract by 50%. Our integration strategy is working—we're accelerating growth by unifying our teams and services.
https://t.co/AqhOicI84f

$ONAR #OTCMarkets #Marketing

[Mark Davis @Icon_of_OTC]

$MAJI updated their profile on Otcmarkets I noticed they now reference Pancreatic cancer and Viral infections...https://t.co/K53Cbb9umI

Exousia Pro, Inc. (EXO), a leader in exosome-based biotechnology, develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. EXO’s breakthrough platform enables the custom production of exosomes with enhanced genetic functionality, capable of selectively targeting specific cells to address diseases with significant unmet medical needs. These engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer, thereby improving patient responsiveness to anticancer therapies. The same platform technology also holds promise for treating a broad spectrum of viral infections.

[Mark Davis @Icon_of_OTC]

Here it is:
BioTuesday Article
"Beyond GMB, Mr. Sheikh says that Exousia’s modular platform is being applied to programs in pancreatic, breast, lung, and colorectal cancers, as well as infectious diseases, where DNA payloads offer uniquely powerful interventions."

$MAJI

[Valentina OTC @ValentinaOTC]

@Icon_of_OTC $MAJI - Thinking they have more FDA applications to file????

[Mark Davis @Icon_of_OTC]

The are pretty much telling us this in the tweet..I believe somewhere, there is mention of Pancreatic cancer and several other forms of cancer...That line seems like they are projecting the future... $MAJI

[Valentina OTC @ValentinaOTC]

@Icon_of_OTC $MAJI - Thinking they have more FDA applications to file????

[Mark Davis @Icon_of_OTC]

This makes sense, but what stands out to me is "We do not want to jeopardize any future applications we have planned" $MAJI...

[NextTel Medical Corp @NexTelMedical]

$MAJI we are waiting for our official notification from the FDA before we make any formal announcement on our Orphan Drug Application.  We do not want to jeopardize any future applications we have planned. This is a very exciting time for the Company, stay tuned for more updates.

[Mark Davis @Icon_of_OTC]

I was wondering when this was gonna happen. Dwyer spent years in the Cannabis world, they had a large manufacturing facility amongst other licenses. This should be an easy home run for $MAJI...

[NextTel Medical Corp @NexTelMedical]

$MAJI: We are exceptionally optimistic about the commercialization path for our CBD-loaded exosome technology. Our President, Matt Dwyer, leverages years of specialized executive experience and established, high-level connections within the California cannabis sector, providing an immediate and strategic advantage. Following the scientific confirmation from our team, Mr. Dwyer initiated successful preliminary discussions with both U.S. and European buyers, validating the strong commercial interest. Sales will commence immediately upon receiving the compelling results of our IRB study, demonstrating the enhanced efficacy of our exosomes. These operations will be managed under a newly formed subsidiary, establishing a swift, scalable pathway to profitability in this multi-billion-dollar market.

[Mark Davis @Icon_of_OTC]

RT @Exousia_Pro:

[Mark Davis @Icon_of_OTC]

People we know $MAJI is going to take off now...ASCM who works with GSTM when they are upside down has come on. The last time they popped on $MAJI ran to $.32 based on what's happening now, I think it could run higher JMHO!!!

[ONAR @BuiltWithOnar]

It's official: The Retina AI acquisition is complete.

This means an immediate uplift in $ONAR recurring revenue and rich cross-sell potential. We are thrilled to begin integrating this incredible technology across our client base.
https://t.co/QJMHoHm4XH

#AI #MarTech #Acquisition

[Mark Davis @Icon_of_OTC]

I think we are all waiting to see the results here.

$MAJI